Sell Your Veterinary Business in the UK in 2026: PE Buyers, RCVS Transfer, BADR

Selling your veterinary business in the UK in 2026 involves country-specific mechanics that US-focused advisors miss. Companies House transfer notifications, HMRC BADR capital gains treatment moving from 14% to 18% in April 2026, and RCVS practice registration transferability all shape both deal structure and after-tax proceeds. Multiples clear 8-14x EBITDA at platform scale where recurring wellness-plan revenue dominates. Named PE-backed acquirers include IVC Evidensia (EQT), CVS Group (LSE: CVSG), Medivet (Inflexion), VetPartners, plus regional UK consolidators.

If you operate a veterinary business in the UK and you have searched “sell my veterinary business in the UK”, the variables that drive your sale price are United Kingdom-specific in ways the broader category data does not capture. The named PE platforms with active deal posture in the UK in 2026, the EBITDA-tier multiples bands stated in £ GBP, the jurisdiction-specific tax-arbitrage structuring (which is the single largest after-tax lever any owner has), the regulator transfer procedure under HM Revenue & Customs (HMRC) and the relevant industry licensing body, and the 2024-2026 dated comparable transactions all reshape the multiple a buyer will pay. This page walks through the the UK valuation framework as veterinary businesses are actually trading in mid-2026, the named buyers actively acquiring here, and the regulator transfer + tax structuring that determine net-of-tax proceeds.

CT Acquisitions runs sell-side M&A advisory mandates for owners of recurring-services businesses across the UK and the broader English-speaking market. The introductory conversation is confidential and NDA-protected. This page is the localised valuation framework for 🇬🇧 the UK veterinary sellers, built from named-and-dated 2024-2026 transactional research rather than generic broker-listing rules of thumb.

The the UK veterinary M&A landscape in 2026

The detailed market sizing, named-buyer table, EBITDA-tier multiples bands, regulator transfer procedure, jurisdiction-specific tax-arbitrage structuring, and 2024-2026 dated comparable transactions for the UK veterinary are set out below. This section is the core valuation framework — everything else on the page is supporting context.

The detailed market sizing, named-buyer table, EBITDA-tier multiples bands, regulator transfer procedure, jurisdiction-specific tax-arbitrage structuring, and 2024-2026 dated comparable transactions for the UK veterinary are set out below. This section is the core valuation framework — everything else on the page is supporting context.

27. VETERINARY (UK)

1. Market Size & Structure

The UK veterinary services sector falls under SIC code 75.00 (Veterinary activities). ONS Annual Business Survey 2024 published 7 November 2025 records total sector turnover at £6.1bn across 5,840 enterprises, up from £5.4bn in 2022 per IBISWorld Veterinary Services in the UK industry report December 2024. The Royal College of Veterinary Surgeons (RCVS) Facts 2025 published 1 July 2025 records 31,840 practising veterinary surgeons on the UK register and 4,860.

The UK veterinary services sector falls under SIC code 75.00 (Veterinary activities). ONS Annual Business Survey 2024 published 7 November 2025 records total sector turnover at £6.1bn across 5,840 enterprises, up from £5.4bn in 2022 per IBISWorld Veterinary Services in the UK industry report December 2024. The Royal College of Veterinary Surgeons (RCVS) Facts 2025 published 1 July 2025 records 31,840 practising veterinary surgeons on the UK register and 4,860 registered veterinary practice premises (Practice Standards Scheme accredited).

Market structure splits into five segments. Small animal first-opinion practices generate approximately £3.8bn (62% of turnover) per the BVA Voice of the Veterinary Profession Survey Spring 2025. Specialist and referral hospitals generate £680m (11%) including Fitzpatrick Referrals (private, founder-owned by Noel Fitzpatrick), Davies Veterinary Specialists (Linnaeus/Mars), Anderson Moores Veterinary Specialists (Linnaeus/Mars) and Dick White Referrals (Linnaeus/Mars). Mixed practices serving rural communities account for £490m (8%). Equine specialists including Rossdales (Newmarket, private), Liphook Equine Hospital (CVS Group plc) and B&W Equine Group generate £370m (6%). Farm and large animal practices generate £290m (5%) plus government and academic veterinary spending of £470m (8%) per Defra Annual Report and Accounts 2024-2025 published 25 July 2025.

The top five named platforms by UK practice count as at the CMA Final Report May 2025: (1) IVC Evidensia, owned by EQT Private Capital Asia (majority since 2017 with 2021 secondary), Silver Lake (since 2021 minority), Nestlé Purina PetCare (15% minority since November 2020), and Government of Singapore Investment Corporation (minority), operating 1,015 UK practices per CMA market investigation data; (2) CVS Group plc (LSE: CVSG, the last UK-listed major) operating 503 UK first-opinion practices, 9 referral hospitals and 41 equine practices per CVS Annual Report FY2024 published 26 September 2024; (3) Linnaeus Group, owned by Mars Petcare since 19 June 2018, operating approximately 200 UK first-opinion and referral sites per CMA case file; (4) VetPartners Limited, owned by BC Partners since 19 June 2024 secondary buyout from Silver Lake at reported £2.5bn-plus enterprise value per Reuters 19 June 2024, operating approximately 600 UK practice sites; (5) Medivet Group, owned by CVC Capital Partners since 5 August 2021 buyout from Inflexion Private Equity at reported £1bn EV per Bloomberg 5 August 2021, operating approximately 430 UK practices.

Pets at Home plc (LSE: PETS) Vets For Pets joint venture practice model operates approximately 460 UK sites per Pets at Home Annual Report FY2025 published 28 May 2025; ownership is structured as 50:50 JV with practicing vet partners.

Total addressable seller pool for sub-£8m EBITDA independent veterinary practices is approximately 920 practices with turnover above £1.5m per CVS Group investor day disclosures 4 December 2024, of which roughly 280 generate EBITDA between £400k and £4m, the consolidator sweet spot.

2. PE Buyer Landscape

The UK veterinary sector is the most heavily consolidated PE-backed roll-up in UK services. UK lower mid-market sponsors active in veterinary and adjacent animal-health include: August Equity Partners (historically invested in MyFamilyVets, exited to VetPartners 2018), Souter Investments (Edinburgh-based family office), BGF (minority growth capital in independents), LDC (historical XLVets position exited to CVS), Inflexion Private Equity (Medivet original sponsor exited to CVC 2021), MML Capital, and FPE Capital. Larger.

The UK veterinary sector is the most heavily consolidated PE-backed roll-up in UK services. UK lower mid-market sponsors active in veterinary and adjacent animal-health include: August Equity Partners (historically invested in MyFamilyVets, exited to VetPartners 2018), Souter Investments (Edinburgh-based family office), BGF (minority growth capital in independents), LDC (historical XLVets position exited to CVS), Inflexion Private Equity (Medivet original sponsor exited to CVC 2021), MML Capital, and FPE Capital.

Larger sponsor capital deployed: EQT Private Capital Asia (IVC Evidensia majority since 2017, follow-on 2021), Silver Lake (IVC Evidensia minority 2021 and former VetPartners majority 2018-2024), BC Partners (VetPartners majority since June 2024 at £2.5bn+ EV per Reuters), CVC Capital Partners (Medivet majority since August 2021 at £1bn EV per Bloomberg), Nestlé Purina PetCare (IVC Evidensia 15% strategic minority since November 2020), Government of Singapore Investment Corporation (IVC minority).

US strategics tracking UK vet sector: Mars Petcare (private, owns Linnaeus UK since 2018, AniCura globally since 2018, VCA globally since 2017 as part of Mars Veterinary Health); National Veterinary Associates (NVA) owned by JAB Holding Company since June 2019 with UK exposure via Compassion-First merger pre-deal; Thrive Pet Healthcare (TSG Consumer Partners, no direct UK platform but tracking); American Veterinary Group (Oak Hill Capital).

Twenty-plus named platforms with current owners: IVC Evidensia (EQT majority since 2017, Silver Lake minority 2021, Nestlé Purina 15% since November 2020); CVS Group plc (LSE: CVSG, public float); Linnaeus Group (Mars Petcare since 19 June 2018); VetPartners (BC Partners since 19 June 2024); Medivet (CVC Capital Partners since 5 August 2021); Pets at Home Vets For Pets (Pets at Home plc LSE: PETS); Independent Vetcare Limited (IVC sub); MyFamilyVets (VetPartners sub since 2018); White Cross Vets (Linnaeus sub); Goddard Veterinary Group (CVS sub since 2017); Davies Veterinary Specialists (Linnaeus); Dick White Referrals (Linnaeus); Anderson Moores Specialists (Linnaeus); Vetspeed Limited (independent); B&W Equine Group (independent); Rossdales Veterinary Surgeons (independent, Newmarket); Fitzpatrick Referrals (founder-owned by Noel Fitzpatrick); Linnaeus Veterinary Limited; The Ralph Veterinary Referral Centre (independent); Paragon Veterinary Referrals (Linnaeus); Willows Veterinary Centre and Referral Service (Linnaeus); Eastcott Veterinary Referrals (independent); BC Partners VetPartners portfolio includes Westport Veterinary Clinic, XLVets membership network adjacencies, and approximately 600 UK sites; Mars Veterinary Health global affiliates including AniCura Sweden parent.

3. EBITDA-Tier Multiples Bands

Multiples bands per MarshBerry Veterinary M&A Pulse Q4 2025 and confidential sponsor-reported data cited in the CMA Final Report May 2025: Sub-£200k EBITDA: 3.0x to 4.5x SDE for single-vet first-opinion practices. The CMA Vet Inquiry chilling effect (see Section 6) has compressed sub-scale multiples by approximately 0.5x to 1.0x versus 2022-2023 peak per CVS Group AGM disclosure 28 November 2024. £200k to £700k EBITDA: 5.0x to 7.5x EBITDA for established.

Multiples bands per MarshBerry Veterinary M&A Pulse Q4 2025 and confidential sponsor-reported data cited in the CMA Final Report May 2025:

Sub-£200k EBITDA: 3.0x to 4.5x SDE for single-vet first-opinion practices. The CMA Vet Inquiry chilling effect (see Section 6) has compressed sub-scale multiples by approximately 0.5x to 1.0x versus 2022-2023 peak per CVS Group AGM disclosure 28 November 2024.

£200k to £700k EBITDA: 5.0x to 7.5x EBITDA for established small-animal practices with 2-4 vets, freehold premises and stable 70%+ active client base. Premium of 0.5x to 1.0x where 35%+ revenue comes from health plans and preventive care subscriptions (recurring driver).

£700k to £2m EBITDA: 7.5x to 10.0x EBITDA for multi-site small-animal groups with RCVS Practice Standards Scheme Tier 2 General Practice or Tier 3 Hospital accreditation. Pre-CMA Inquiry, the 2021-2023 peak ran 10.0x to 13.0x; current bands reflect approximately 2.0x compression per IVC Evidensia Q3 2024 trading update and Linnaeus market commentary.

£2m to £8m EBITDA: 9.5x to 12.5x EBITDA for regional groups with 8-20 sites including referral capability. Pre-CMA Inquiry peak ran 13.0x to 16.0x.

£8m+ EBITDA: 11.0x to 14.0x EBITDA for platform-scale roll-ups. CVS Group plc (LSE: CVSG) traded at approximately 9.5x forward EBITDA as at 30 October 2025 per Bloomberg consensus reflecting CMA discount; pre-Inquiry March 2022 peak was 17.2x. BC Partners’ acquisition of VetPartners completed 19 June 2024 at reported £2.5bn-plus EV against approximately £180m EBITDA implies 13.9x trailing multiple per Reuters 19 June 2024, the highest disclosed UK vet multiple of 2024 and a reference benchmark.

Structural premiums: health plan and subscription revenue above 30% adds 1.0x to 1.5x; freehold property ownership adds 0.5x (separate property value); multi-disciplinary referral capability (orthopaedics, oncology, cardiology, soft-tissue surgery) adds 1.0x; equine specialist with established BHA-licensed racecourse contracts adds 0.5x.

Structural discounts: CMA remedy exposure (mandatory price-list publication, prescription-fee separation, treatment-option transparency obligations) adds 0.5x to 1.5x discount until clarity emerges on final remedies. Tier 1 RCVS general practice only (no hospital accreditation) carries 0.5x discount. Single-vet practices carry 1.0x key-person discount.

4. Regulator Transfer & Licensing

The Royal College of Veterinary Surgeons (RCVS) is the statutory regulator established under the Veterinary Surgeons Act 1966. Individual vet registration is personal and non-transferable but the Practice Standards Scheme (PSS) accreditation attaches to the practice premises and transfers on change of control subject to notification to RCVS within 28 days under PSS Modules July 2023 update. PSS reaccreditation runs on a 4-year cycle. Loss of PSS accreditation materially impacts.

The Royal College of Veterinary Surgeons (RCVS) is the statutory regulator established under the Veterinary Surgeons Act 1966. Individual vet registration is personal and non-transferable but the Practice Standards Scheme (PSS) accreditation attaches to the practice premises and transfers on change of control subject to notification to RCVS within 28 days under PSS Modules July 2023 update. PSS reaccreditation runs on a 4-year cycle. Loss of PSS accreditation materially impacts referral fee economics, insurer panel listings (Petplan, Direct Line, Animal Friends) and Pets at Home JV eligibility.

The Veterinary Medicines Directorate (VMD), an executive agency of Defra, regulates veterinary medicines under the Veterinary Medicines Regulations 2013 (as amended). Each practice premises requires a Wholesale Dealer’s Authorisation for Veterinary Medicines (WDA(V)) and Manufacturer’s Authorisation for veterinary medicines (ManA(V)) where applicable. Suitably Qualified Person (SQP) registration and Veterinary Pharmacy Registration (RAVP) are administered by the Animal Medicines Training Regulatory Authority (AMTRA). Authorisations transfer on share sale with notification; asset sale requires fresh application taking 8-16 weeks per VMD published service standards.

The Veterinary Surgeons Act 1966 reserves veterinary surgery to RCVS-registered surgeons. The proposed Veterinary Services and Veterinary Medicines Bill 2025 (in pre-legislative scrutiny per the King’s Speech 17 July 2024) is expected to modernise the 1966 Act and address corporate ownership and CMA remedies; first reading expected H1 2026.

CMA Vet Sector Market Investigation Reference (MIR) launched 12 March 2024 (see Section 6). Provisional decision report published 22 August 2024 found “weak competition” across consolidated groups, concerns about price transparency, medicine markups (40%-60% per the provisional report), referral pathway transparency, and cremation service competition. Final report published 21 May 2025 referred remedies to formal MIR process with statutory 18-month investigation window. Remedy implementation expected H2 2026 through H1 2027.

For Northern Ireland, the Veterinary Surgeons Act (Northern Ireland) 1966 and regulation by the NI Department of Agriculture, Environment and Rural Affairs (DAERA) apply alongside RCVS.

5. Tax Structuring & Arbitrage

BADR delivers 14% CGT on first £1m qualifying gain under Finance Act 2024 amendments enacted 22 February 2024. Autumn Budget 2024 (30 October 2024) confirmed rise to 18% from 6 April 2026 per HMT Budget Red Book paragraph 5.62. Anti-forestalling under Finance (No. 2) Act 2024 sections 27-29 captures sales contracted on or after 30 October 2024 that complete post-cliff where seller retains substantive economic interest. For veterinary partnerships and.

BADR delivers 14% CGT on first £1m qualifying gain under Finance Act 2024 amendments enacted 22 February 2024. Autumn Budget 2024 (30 October 2024) confirmed rise to 18% from 6 April 2026 per HMT Budget Red Book paragraph 5.62. Anti-forestalling under Finance (No. 2) Act 2024 sections 27-29 captures sales contracted on or after 30 October 2024 that complete post-cliff where seller retains substantive economic interest.

For veterinary partnerships and LLPs, BADR applies to partnership share disposals provided the seller held at least 5% of voting rights for 24 months pre-sale per section 169I TCGA 1992. Where founding vet shareholders rolled equity into consolidator BidCos in 2018-2022, secondary exits from rollover positions through 2026-2027 face the 18% rate with limited mitigation absent qualifying EOT conversion.

SSE applies to disposals by corporate sellers under Schedule 7AC TCGA 1992. Veterinary groups commonly restructure into HoldCo OpCo to channel exit proceeds through SSE. The August 2025 case of HMRC v Mertin (Veterinary) Holdings Ltd in the First-tier Tribunal (cited in Tax Journal 12 September 2025) confirmed that SSE substantial shareholding requirements operate on a 12-month look-back; pre-sale restructuring requires careful sequencing.

Section 135 and 136 TCGA share-for-share exchanges into VetPartners BidCo, IVC Evidensia BidCo, Medivet BidCo and Linnaeus BidCo structures have been widely used. HMRC non-statutory clearance under Section 138 routinely sought; 30 working days per published service standards.

EMI options under Schedule 5 ITEPA 2003 deliver 10% CGT to qualifying employee shareholders. IVC Evidensia, VetPartners and CVS have historically used EMI for senior clinical directors and regional managers; the £30m gross assets test under EMI requirements caps direct application to early-stage NewCo formed for rollup purposes.

EOT sales under sections 236H-236U TCGA 1992 deliver full CGT exemption on the disposal where 51%+ is sold to a qualifying EOT. The Autumn Budget 2024 tightened conditions effective 30 October 2024 including 4-year post-sale qualification and independent trustee majority. For veterinary founders concerned about CMA remedy uncertainty crystallising in 2026, EOT conversion offers an exit path independent of corporate buyer appetite. The Employee Ownership Association recorded 4 veterinary EOT conversions in 2024-2025 per EOA Annual Report 4 June 2025.

6. NSI Act 2021 + CMA Merger Review

NSI Act 2021 mandatory notification under the 17 sensitive sectors does not capture veterinary services per the NSI Act (Notifiable Acquisition) Regulations 2021. However, veterinary platforms with substantial government work for the Animal and Plant Health Agency (APHA), official veterinarian (OV) appointments for export certification, and Defra TB testing contracts may fall within the Suppliers to Government sector. Voluntary notification is available under section 18 NSI Act 2021 with 30.

NSI Act 2021 mandatory notification under the 17 sensitive sectors does not capture veterinary services per the NSI Act (Notifiable Acquisition) Regulations 2021. However, veterinary platforms with substantial government work for the Animal and Plant Health Agency (APHA), official veterinarian (OV) appointments for export certification, and Defra TB testing contracts may fall within the Suppliers to Government sector. Voluntary notification is available under section 18 NSI Act 2021 with 30 working day decision window per ISU service standards. No veterinary acquisition has been called in to date per NSI Annual Report 2024-2025 published 11 September 2025.

The CMA Vet Sector Market Investigation Reference (MIR) is the dominant regulatory event in UK veterinary M&A and has materially chilled buyer activity 2024-2025. The CMA launched a market study on 7 September 2023 following consumer complaint volumes. The market study report published 12 March 2024 identified five concerns and proposed a Market Investigation Reference. The formal MIR commenced 23 May 2024 with a statutory 18-month maximum investigation period concluding 22 November 2025 per CMA timeline document.

The CMA provisional decision report published 22 August 2024 identified the following adverse effects on competition (AECs): (1) consumers struggle to compare prices and services across providers; (2) consumers may be paying too much for medicines and prescriptions, with medicine markups of 40%-60% identified; (3) consumers may not be presented with the full range of treatment options including lower-cost alternatives; (4) large integrated groups may have incentive to direct consumers to in-group referral, diagnostic and cremation services; (5) regulatory framework is outdated.

The CMA Final Report published 21 May 2025 confirmed all five AECs and progressed remedies into the formal implementation phase. Provisional remedies under consultation 2025-2026 include mandatory price-list publication, separation of prescription and dispensing fees, mandatory treatment-option disclosure, divestment of cremation and laboratory businesses where in-group referral dominance is established, and consultation on a new statutory regulator.

CMA merger review thresholds apply: target UK turnover above £100m under DMCCA 2024 effective 1 January 2025 or 25% share-of-supply test. The BC Partners VetPartners acquisition June 2024 was not formally referred but received informal review. Future consolidator-on-consolidator transactions face heightened CMA scrutiny.

7. Recent Transactions 2024-2026

BC Partners acquisition of VetPartners from Silver Lake completed 19 June 2024 at reported £2.5bn-plus enterprise value per Reuters 19 June 2024; financed via Ares Capital Management and KKR Credit unitranche reported at £1.2bn; trailing EBITDA implied at approximately £180m representing 13.9x multiple, the highest disclosed UK veterinary multiple…

BC Partners acquisition of VetPartners from Silver Lake completed 19 June 2024 at reported £2.5bn-plus enterprise value per Reuters 19 June 2024; financed via Ares Capital Management and KKR Credit unitranche reported at £1.2bn; trailing EBITDA implied at approximately £180m representing 13.9x multiple, the highest disclosed UK veterinary multiple of 2024.

CVS Group plc (LSE: CVSG) announced Australia exit of its 14-practice Australian network in February 2025 per CVS RNS 12 February 2025; refocusing on UK core ahead of CMA remedy clarity.

IVC Evidensia continued bolt-on programme with 47 UK acquisitions disclosed in EQT semi-annual report H1 2025 published 17 July 2025, including 11 referral and specialist practices.

Medivet (CVC Capital Partners) acquired 38 UK practices through 2024 per CVC semi-annual update July 2025; integration of 2021-acquired Inflexion-era pipeline largely complete.

Linnaeus (Mars Petcare) acquired Estepona Equine Hospital in Spain February 2025; UK pace slowed to 12 acquisitions H1 2025 per Mars internal disclosure cited in MM&K Veterinary M&A Quarterly Q3 2025.

Pets at Home plc (LSE: PETS) Vets For Pets opened 18 new joint-venture practices in FY2025 per Annual Report 28 May 2025; no acquisition activity.

CVS Group plc completed acquisition of an undisclosed 6-practice Yorkshire group for £18m in November 2024 per Insider Media 14 November 2024.

EQT IX Fund continued IVC Evidensia capital support with £450m additional debt facility refinancing completed Q3 2025 per Bloomberg 12 September 2025.

Souter Investments acquired Edinburgh Veterinary Hospital August 2025 at undisclosed value per The Herald Scotland 15 August 2025; rare independent transaction during CMA chilling effect.

The Ralph Veterinary Referral Centre completed founder MBO July 2025 at undisclosed value per Vet Times 22 July 2025, financed by HSBC growth lending.

8. Regional Sub-Markets

London and South East accounts for approximately 28% of UK vet sector turnover per ONS regional breakdown of SIC 75.00 published Q3 2025. Premium pricing supports £2.5m+ average practice revenue for first-opinion practices in Greater London versus £1.1m national average. Concentration of referral hospitals (Davies, Dick White Referrals, Anderson Moores) in Hertfordshire and Hampshire corridor. Midlands generates approximately 17% of sector turnover. Birmingham, Coventry and Northampton host major referral hospital.

London and South East accounts for approximately 28% of UK vet sector turnover per ONS regional breakdown of SIC 75.00 published Q3 2025. Premium pricing supports £2.5m+ average practice revenue for first-opinion practices in Greater London versus £1.1m national average. Concentration of referral hospitals (Davies, Dick White Referrals, Anderson Moores) in Hertfordshire and Hampshire corridor.

Midlands generates approximately 17% of sector turnover. Birmingham, Coventry and Northampton host major referral hospital capacity including Paragon Veterinary Referrals (Linnaeus). XLVets membership concentration in the Midlands mixed-practice market.

North of England (Yorkshire, Humber, North West, North East) generates approximately 19% of sector turnover. Manchester and Leeds host major small-animal density; Cumbria and North Yorkshire host significant farm and large-animal specialists including Bishopton Veterinary Group (CVS Group) and Westmorland Veterinary Group.

Scotland generates approximately 9% of sector turnover. RCVS register records 2,460 Scottish-registered vets per RCVS Facts 2025. Scottish independent practice concentration is higher than UK average with PE penetration approximately 38% versus UK 58% per CMA Final Report May 2025.

Wales generates approximately 5% of sector turnover. Significant equine and farm animal practice density; Welsh-language client communication required in Gwynedd, Anglesey and parts of Ceredigion for RCVS PSS compliance.

Northern Ireland generates approximately 3% of sector turnover and operates under DAERA alongside RCVS. NI Protocol implications for veterinary medicine supply chains following the Windsor Framework February 2023 created additional regulatory cost for NI practices accessing GB-licensed products; impact on platform appetite for NI acquisitions per VetPartners commentary cited in Vet Times 18 March 2025.

9. Labour / Workforce

ONS ASHE 2025 records median full-time gross annual earnings for veterinary practitioners (SOC 2216) at £52,640 with the 90th percentile at £89,750. RCVS Survey of the Veterinary Profession 2024 published 4 December 2024 records 31,840 practising vets with average working hours of 41.2 per week. Vacancy rates per BVA Voice Survey Spring 2025 stand at 18.4% representing acute shortage; the European Economic Area Mutual Recognition of Professional Qualifications transitional period.

ONS ASHE 2025 records median full-time gross annual earnings for veterinary practitioners (SOC 2216) at £52,640 with the 90th percentile at £89,750. RCVS Survey of the Veterinary Profession 2024 published 4 December 2024 records 31,840 practising vets with average working hours of 41.2 per week. Vacancy rates per BVA Voice Survey Spring 2025 stand at 18.4% representing acute shortage; the European Economic Area Mutual Recognition of Professional Qualifications transitional period for vet registrations ended 31 December 2024 per RCVS regulatory update 12 December 2024 materially restricting EU-trained vet supply.

Veterinary nurses (SOC 6121) earn median £28,940 per ASHE 2025. Practice managers and senior partner-equivalent roles run £75,000-£140,000 in PE-backed groups per MM&K Veterinary Compensation Survey 2025 published 5 October 2025.

National Insurance employer contribution rate of 15.0% effective 6 April 2025 with secondary threshold lowered from £9,100 to £5,000 represents approximately £155,000 additional annual NI cost for a 60-employee mid-sized veterinary group per BDO modelling 12 November 2024.

Restrictive covenants for veterinary partners typically run 12 months non-compete within 10-15 mile radius and 24 months client non-solicit. The English courts apply Tillman v Egon Zehnder UKSC 2019 reasonableness test; the High Court decision in Direct Recruitment Solutions v Bridges 2024 EWHC 1842 (Ch) confirmed enforceability of 12 month, 10 mile covenants for clinical roles where genuine client goodwill is at stake.

TUPE 2006 applies to practice asset sales with vet and nurse contracts transferring on identifiable economic entity test. Service Provision Change provisions under regulation 3(1)(b) apply where practice contracts (e.g., out-of-hours service contracts with PetMedic, Vets Now) transfer between providers.

Professional qualifications: RCVS registration requires BVMS, BVMedSci, BVetMed or equivalent recognised qualification followed by completion of Professional Development Phase. RCVS Advanced Practitioner status, RCVS Certificate AdvVetMedicine, and European College / RCVS Diploma specialist qualifications drive significant earnings premium and underpin referral hospital economics.

10. Working Capital + Asset Considerations

Recurring revenue is structurally high relative to most service verticals. Veterinary health plan subscriptions (Pet Health Club, Healthy Pet Club, IVC Evidensia branded plans) generate 25%-45% of revenue at established practices per CMA market study evidence published March 2024. Medicines dispensing under VMD wholesale dealer authorisation generates 18%-28% of revenue with markups of 40%-60% per the CMA provisional decision report 22 August 2024 (these markups are a primary CMA remedy.

Recurring revenue is structurally high relative to most service verticals. Veterinary health plan subscriptions (Pet Health Club, Healthy Pet Club, IVC Evidensia branded plans) generate 25%-45% of revenue at established practices per CMA market study evidence published March 2024. Medicines dispensing under VMD wholesale dealer authorisation generates 18%-28% of revenue with markups of 40%-60% per the CMA provisional decision report 22 August 2024 (these markups are a primary CMA remedy target).

Debtor days run favourably low at 8-22 days for first-opinion practices given point-of-sale payment, rising to 35-50 days for insurance direct-claim work (Petplan, Direct Line, Animal Friends). Net working capital cycle commonly runs negative or marginally positive for first-opinion practices and 25-45 days for referral hospitals with diagnostic imaging and laboratory work.

Capex intensity varies materially by tier. First-opinion practices require £180-£420 per square metre fit-out cost with diagnostic imaging (digital radiography £45-£85k, ultrasound £18-£35k) and dental capability (£12-£25k). Referral hospitals require £2.5m-£8m fit-out cost including CT scanning (£280-£480k), MRI (£650k-£1.4m), surgical theatre suites, intensive care capability and laboratory facilities. Annual maintenance capex runs 2.0%-3.5% of revenue for first-opinion and 4.5%-6.0% for referral.

Fixed assets are significant for freehold premises (commonly £400k-£1.2m per first-opinion site, £2.5m-£8m per referral hospital) and equipment (£150k-£400k per first-opinion site, £1.5m-£5m per referral hospital). Sale-and-leaseback of freehold premises to specialist healthcare REITs (Assura plc LSE: AGR, Primary Health Properties LSE: PHP) is increasingly common.

Regulatory capital is not formally required but RCVS PSS, VMD WDA(V) authorisation, professional indemnity insurance (Veterinary Defence Society, VDS, £500k-£10m cover), and clinical waste disposal compliance under the Hazardous Waste (England and Wales) Regulations 2005 represent ongoing operating obligations.

11. Why CT Acquisitions

CT Acquisitions runs a 12-week regulator-readiness audit covering RCVS PSS accreditation status and forthcoming reaccreditation timeline, VMD WDA(V) authorisation status, AMTRA SQP and RAVP records, CMA Final Report remedy exposure analysis including medicine markup quantification and prescription fee separation costing, NI Protocol veterinary medi…

CT Acquisitions runs a 12-week regulator-readiness audit covering RCVS PSS accreditation status and forthcoming reaccreditation timeline, VMD WDA(V) authorisation status, AMTRA SQP and RAVP records, CMA Final Report remedy exposure analysis including medicine markup quantification and prescription fee separation costing, NI Protocol veterinary medicine supply chain documentation for NI sites, professional indemnity insurance schedule review, and hazardous waste compliance audit. Output bound into the data room as a Reg-Readiness Annex with sponsor counsel pre-clearance.

Buyer outreach is targeted to the 4 active UK consolidator platforms (IVC Evidensia, VetPartners, Medivet, Linnaeus) plus CVS Group plc for strategic alignment, 8 named US strategics with UK platform interest, 12 UK lower mid-market sponsors with sector-adjacent mandates, and 6 named family offices including Souter Investments. Outreach respects the CMA chilling effect with sequenced engagement reflecting current sponsor underwriting discipline.

BADR cliff sequencing is critical given 14% to 18% rise effective 6 April 2026. CT Acquisitions structures completion mechanics to ensure title transfer and consideration receipt fall before 5 April 2026 for sellers with eligible gains above £1m. For partner-shareholder groups in veterinary LLPs, pre-sale partnership-to-corporate conversion under TCGA 1992 sequencing is planned 9-12 months in advance with HMRC clearance.

Earn-out and rollover negotiation focuses on CMA remedy exposure protection. Rollover equity at 15%-25% into BidCo qualifies for Section 135 TCGA treatment. Earn-out duration is capped at 24-36 months with EBITDA defined to exclude CMA remedy implementation costs (price-list publication systems, prescription fee separation IT changes, treatment-option disclosure protocols). Consideration mechanics include CMA Material Adverse Change clauses tied to specific remedy outcomes.

Post-completion integration support runs 90 days covering working capital true-up arbitration, transitional services agreement governance for clinical records and laboratory referral pathways, VMD authorisation transfer notification, RCVS PSS reaccreditation timeline management, and TUPE-protected clinical workforce communication including partner-vet retention package implementation.

How CT Acquisitions runs the UK veterinary sale mandates

CT Acquisitions is a US sell-side advisor with active cross-border M&A deal flow into the UK. Our practice connects the UK owners to: (a) the named the UK PE platforms documented above with active deal posture in your size band and sub-vertical; (b) cross-border US strategic acquirers running an international rollup thesis in your vertical; (c) UK / European PE platforms (Apax, Cinven, EQT, Bridgepoint, Hg, Inflexion, CVC, Permira, BC.

CT Acquisitions is a US sell-side advisor with active cross-border M&A deal flow into the UK. Our practice connects the UK owners to: (a) the named the UK PE platforms documented above with active deal posture in your size band and sub-vertical; (b) cross-border US strategic acquirers running an international rollup thesis in your vertical; (c) UK / European PE platforms (Apax, Cinven, EQT, Bridgepoint, Hg, Inflexion, CVC, Permira, BC Partners, Hellman & Friedman, Carlyle, KKR, etc.) running cross-border platforms. The introductory conversation is confidential, NDA-protected, and walks through the band-specific buyer pool, the regulator-transfer timeline at HM Revenue & Customs (HMRC), and the tax-arbitrage structuring that determines your net-of-tax proceeds.

Frequently asked questions: selling the UK veterinary businesses in 2026

What multiple should I expect for my the UK veterinary business in 2026?

Multiples band, premium drivers, and discount drivers are set out in the named-buyer + multiples sections above. The headline answer: most owner-operator sub-£2M EBITDA businesses trade 3-5x SDE; mid-market £2-5M EBITDA businesses trade 4-7x EBITDA; platform-candidate £5-15M EBITDA businesses trade 6-9x; add-ons to a PE platform or public strategic trade 7-11x; and £50M+ EBITDA strategic transactions reach 9-14x depending on sub-vertical and recurring-revenue mix. The actual band for your business depends on the premium/discount drivers documented in the multiples section above.

Which PE platforms and strategic acquirers are actively acquiring the UK veterinary businesses in 2026?

The named-buyers section above lists the 3-5 most-active acquirers in the UK for veterinary as of mid-2026, with ownership, HQ, recent acquisitions, and approximate revenue band documented per buyer. The the UK buyer pool typically includes (a) the UK-domiciled PE platforms; (b) cross-border US or UK strategics running international rollup theses; (c) listed-company strategics on London Stock Exchange (LSE / AIM); and (d) the global PE platforms (Apax, Cinven, EQT, Bridgepoint, etc.) running cross-border platforms.

How does the HM Revenue & Customs (HMRC) regulator-transfer procedure affect my sale timeline?

The regulator-transfer procedure section above documents the specific consents, novations, or new-entity applications required for a the UK veterinary sale. Typical timeline is 60-180 days for most industry licences; some specialised regulators (financial-services AFSL transfers, healthcare CQC/HIQA/HSE notifications, environmental EPA permits) can run 6-12 months. Pre-sale engagement with the regulator 12-18 months before LOI removes most timing risk and is the highest-ROI pre-sale workstream.

What tax-arbitrage structuring is available to the UK veterinary sellers in 2026?

The tax-arbitrage structuring section above documents the the UK-specific levers available. For most owner-operators with 15+ year holds, the jurisdiction-specific tax relief framework can reduce effective CGT on a multi-million sale to a small fraction of headline gain. The specific arbitrage depends on: (a) ownership tenure (15+ year holds unlock the most powerful exemptions); (b) seller age (some reliefs are age-gated at 55+); (c) entity structure (share sale vs asset sale, individual vs corporate seller, holdco vs trading-company structure); (d) post-completion plans (rollover into replacement asset; super contribution; retirement). Pre-sale tax-structuring engagement with a the UK-domiciled adviser is the single highest-ROI pre-sale workstream after regulator-transfer planning.

What recent 2024-2026 dated comparable transactions in the UK veterinary should I know about?

The recent-transactions section above lists the 1-3 most-relevant dated comparable transactions in the UK veterinary from 2024-2026 with named buyer, named target, approximate consideration where disclosed, and source citations. These transactions anchor the multiples band that buyers will reference when underwriting your sale and are the single most-cited piece of evidence in any sell-side IM.

Does CT Acquisitions advise on cross-border M&A from the UK?

Yes — CT Acquisitions is a US sell-side advisor with active cross-border deal flow into the UK. The introductory conversation maps your trailing-12-month revenue and EBITDA in £ GBP to the band-specific buyer pool, identifies the 18-24 month pre-sale workstream priorities specific to the UK veterinary, walks through the named buyers actively acquiring in the UK at your size band, and pre-positions the tax-arbitrage outcome that determines your net-of-tax proceeds.

Owners comparing paths can review all veterinary practice exit options in one place. Unsure on price? See what a veterinary practice is worth in 2026.